The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Systolic and diastolic blood pressure control in antihypertensive drug trials
Abstract
All published studies agree that hypertension is a poorly diagnosed and treated condition [1,2]. That is, (i) in all countries, the number of subjects in which hypertension is identified is noticeably smaller than that suffering from a blood pressure elevation; (ii) individuals who, after the diagnosis of hypertension, undergo antihypertensive treatment are even less; and (iii) those who have their blood pressure reduced below 140/90 mmHg (systolic/diastolic) because of treatment are no more than a minimal fraction of the overall or even the treated hypertensive population. Indeed, the world situation is even worse than it appears from these data because adequate antihypertensive treatment is poorly implemented even in patients with diabetes [3], nephropathy [4] or prior myocardial infarction [5,6], in whom blood pressure reductions have extremely large life- or disease-saving effects. Furthermore, control rate is particularly low for systolic blood pressure [7,8], which prevails over the diastolic counterpart in determining the overall risk profile [9,10]. Finally, the number of patients with controlled blood pressures becomes dramatically small if values well below 140/90 mmHg (i.e. those offering the greatest degree of protection in several conditions) are considered. Two main explanations have received large credit for the frequent lack of blood pressure control in the treated hypertensive population. One explanation is that, for a variety of reasons, patient compliance to treatment is low [11]. The other is that physicians contribute to this phenomenon in several ways: failure to properly inform and motivate patients; inability to see them as often as needed; and insistance on moving from one monotherapy to another when the antihypertensive response is inadequate without resorting to combination of two or more drugs, thus envisaging a multimechanicistic approach to a multifactorially governed variable such as blood pressure [12]. The above explanations imply that when patient compliance and the expertise of physicians are adequate, blood pressure can be effectively lowered to goal levels. This may be the case for diastolic but not for systolic values, however. Figure 1 shows the blood pressure values in several recent controlled trials on antihypertensive individuals [13–22], that is under conditions in which patient motivation and adherence to treatment on one side, and the ability of physicians to use appropriate drug combinations and doses on the other, unquestionably met high standards. It can be seen that whenever the initial blood pressures were high, treatment was accompanied by large blood pressure reductions. However, while the achieved average diastolic blood pressure was almost invariably well below 90 mmHg and even 80 mmHg, the concomitant systolic value remained above or only slightly below 140 mmHg, the number of individual patients with ‘on treatment’ values below 90 and 140 mmHg being approximately 90 and 50%, respectively [13–22]. This is also the case in diabetic hypertensive patients (Fig. 2) in whom the achieved blood pressure values were higher than in non-diabetic patients despite the use of a larger number of drugs (Fig. 3) [23–34]. Thus, the conclusion can be drawn that even when patient compliance and physicians’ expertise are ensured, systolic blood pressure control is neither frequently nor easily obtained. Furthermore, this goal requires drug doses and combinations that go far beyond those necessary for diastolic blood pressure control. This should be kept in mind when recommendations to lower systolic blood pressure to values well below 140 mmHg, or even 130 mmHg, are given to general practitioners as if they were realistic values to obtain in their patients [1,2].Fig. 1: Effects of antihypertensive drug treatment on systolic (S) and diastolic (D) blood pressure (BP) in trials on essential hypertensive patients. Blood pressure values at trial entry (B) and values achieved during treatment (T) are shown for each trial. Dashed horizontal lines refer to goal blood pressure values indicated by International Guidelines to be achieved during treatment. Based on previously published data [13–22].Fig. 2: Effects of antihypertensive drug treatment on systolic (S) and diastolic (D) blood pressure (BP) in diabetic hypertensive patients of several trials. Values at trial entry and during treatment are shown for each trial. Dashed horizontal lines refer to goal blood pressure values indicated by International Guidelines to be achieved during treatment. Based on previously published data [23–32].Fig. 3: Systolic (S) and diastolic (D) blood pressure (BP) values achieved during treatment in three trials performed in diabetic hypertensives. Data are shown as mean values. The number of drugs employed in these patients are reported at the bottom. Based on previously published data [14,15,31].We see three possibilities ahead: (i) to accept that optimal systolic blood pressure control will neve
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
Dahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08089-3 · Cited by 5,407
(1997) · Archives of Internal Medicine · doi:10.1001/archinte.1997.00440420033005 · Cited by 3,777
(1999) · Journal of Hypertension · doi:10.1097/00004872-199917020-00001 · Cited by 3,695
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
Parving, H.-H., Lehnert, H., Bröchner-Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011489 · Cited by 2,873
Cited by
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,655
Mancia, G., De Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G., Grassi, G., Heagerty, A. M., Kjeldsen, S. E., Laurent, S., et al. (2007) · Journal of Hypertension · doi:10.1097/hjh.0b013e3281fc975a · Cited by 5,824
Self-citationMancia, G., Fagard, R., Narkiewicz, K., Redón, J., Zanchetti, A., Böhm, M., Christiaens, T., Cifkova, R., De Backer, G., Dominiczak, A., et al. (2013) · Journal of Hypertension · doi:10.1097/01.hjh.0000431740.32696.cc · Cited by 5,655
Self-citationDahlöf, B., Sever, P. S., Poulter, N. R., Wedel, H., Beevers, D. G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67185-1 · Cited by 2,909
Authors/Task Force Members:, Mancia, G., De Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G., Grassi, G., Heagerty, A. M., Kjeldsen, S. E., et al. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehm236 · Cited by 2,384
Self-citation
Metadata
- Authors
- Mancia, G., & Grassi, G.
- Venue
- Journal of Hypertension
- Published
- 2002-08
- Volume
- 20
- Issue
- 8
- Pages
- 1461-1464
- ISSN
- 0263-6352 (ISSN-L)
- OpenAlex
- W1965087670
- Cited by
- 266
- References
- 34
- FWCI
- 11.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Systolic and diastolic blood pressure control in antihypertensive drug trials. https://app.cochat.ai/papers/10.1097/00004872-200208000-00001
- The paper
- Mancia, G., & Grassi, G. (2002). Systolic and diastolic blood pressure control in antihypertensive drug trials. Journal of Hypertension. https://doi.org/10.1097/00004872-200208000-00001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.